Inovio acquires rights to early stage therapies

Inovio Pharmaceuticals (INO) acquires the global (ex-China) rights to therapies for Alzheimer's disease and multiple sclerosis based on the work of DNA researcher Dr. Ben Wang from Fudan University's Shanghai Medical College.

The therapies work by generating inducible regulatory T cells (iTreg). The cells are involved in shutting down immune responses after they have successfully eliminated invading organisms. They have potential in preventing autoimmune and inflammatory diseases.

No financial terms are disclosed.

From other sites
Comments (1)
  • docrog123
    , contributor
    Comments (150) | Send Message
    This will give INO a front row seat with Alz.'s and M.S. and the market with these two is huge, but I think there are 16 other major diseases that are sparked by chronic inflammatory process and I have no doubt the market will expand for the tReg's once this study is complete. The medical community is very well aware of the profound effect of chronic inflammatory problems but I don't see much being done yet. NSAIDS have been known for years to create more problems than they solve and they have been prescribed incorrectly for many years so the need is apparent but the remedy has not been forthcoming.
    14 May 2014, 03:46 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs